Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient

Published:2014-12 Issue:2 Volume:12 Page:7-12
ISSN:1359-6349
Container-title:European Journal of Cancer Supplements
language:en
Short-container-title:European Journal of Cancer Supplements

Author:

Colombo Nicoletta

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference21 articles.

1. Optimizing treatment of the partially platinum-sensitive ovarian cancer patient;Colombo;Future Oncol,2013

2. Clinical trials in recurrent ovarian cancer;Friedlander;Int J Gynecol Cancer,2011

3. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin;Markman;J Clin Oncol,1991

4. Management of partially platinum-sensitive relapsed ovarian cancer;Kaye;Eur J Cancer,2008

5. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds;Gore;Gynecol Oncol,1990

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10;British Journal of Cancer;2022-12-08

2. Chemotherapeutic Regimens and Chemotherapy-Free Intervals Influence the Survival of Patients with Recurrent Advanced Epithelial Ovarian Carcinoma: A Retrospective Population-Based Study;International Journal of Environmental Research and Public Health;2021-06-20

3. Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3;International Journal of Gynecologic Cancer;2021-06-08

4. Real-world clinical practice patterns and outcomes for advanced ovarian cancer in Spain (GEICO-42-R study);European Journal of Gynaecological Oncology;2021

5. Virtual clinical trials identify effective combination therapies in ovarian cancer;Scientific Reports;2019-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3